Efficacy of Moxifloxacin against

Animals Anti-Bacterial Agents / pharmacology Disease Models, Animal Moxifloxacin / pharmacology Mycobacterium Infections, Nontuberculous / drug therapy Mycobacterium abscessus / drug effects Zebrafish
Azithromycin Moxifloxacin Mycobacterium abscessus Zebrafish

Journal

Biomedical and environmental sciences : BES
ISSN: 2214-0190
Titre abrégé: Biomed Environ Sci
Pays: China
ID NLM: 8909524

Informations de publication

Date de publication:
20 May 2020
Historique:
received: 27 02 2020
accepted: 11 03 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 29 9 2020
Statut: ppublish

Résumé

Moxifloxacin (MFX) shows good A formulation of Significantly increased survival rate was observed with different AZM concentrations. However, increasing MFX concentration did not result in a significant decrease in ZF survival curve. No significant differences in bacterial burdens by CFU loads were observed between AZM and MFX groups at various concentrations. Bacterial fluorescence intensity in ZF was significantly correlated with AZM concentration. However, with increasing MFX concentration, fluorescence intensity decreased slightly when observed under fluorescence microscope. Transferring rates at various concentrations were comparable between the MFX and AZM groups, with no significant difference. MFX showed limited efficacy against

Identifiants

DOI: 10.3967/bes2020.047 PMID: 32553079
pubmed: 32553079
doi: 10.3967/bes2020.047
doi:

Substances chimiques

Anti-Bacterial Agents 0
Moxifloxacin U188XYD42P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

350-358

Informations de copyright

Copyright © 2020 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.

Auteurs

Wen Juan Nie (WJ)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Zhong Yao Xie (ZY)

Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Shan Gao (S)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Tian Lu Teng (TL)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Wen Qiang Zhou (WQ)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Yuan Yuan Shang (YY)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Wei Jing (W)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Wen Hui Shi (WH)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Qing Feng Wang (QF)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Xue Rui Huang (XR)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Bao Yun Cai (BY)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Jun Wang (J)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Jing Wang (J)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Ru Guo (R)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Qi Ping Ge (QP)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Li Hui Nie (LH)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Xi Qin Han (XQ)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Ya Dong Du (YD)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Nai Hui Chu (NH)

Tuberculosis Department, Beijing Chest Hospital affiliated to Capital Medical University, Beijing 101149, China.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Efficacy of Moxifloxacin against
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Efficacy of Moxifloxacin against
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Efficacy of Moxifloxacin against
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › Moxifloxacine › Efficacy of Moxifloxacin against
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Infections à mycobactéries non tuberculeuses › Efficacy of Moxifloxacin against
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobactéries non tuberculeuses › Mycobacterium abscessus › Efficacy of Moxifloxacin against
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Poissons › Cypriniformes › Cyprinidae › Danio zébré › Efficacy of Moxifloxacin against